CD274 and nonpapillary renal cell carcinoma: There was evidence that the progression-free survival of ccRCC patients treated with avelumab (anti-PD-L1) combined with axitinib is better than that of patients treated with sunitinib alone (Albiges et al., 2020; Tomita et al., 2020).